Market Overview

ARDM INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation on Behalf of Aradigm Corporation Investors


Law Offices of Howard G. Smith continues its investigation on behalf of
Aradigm Corporation ("Aradigm" or the "Company") (NASDAQ: ARDM)
investors concerning the Company and its officers' possible violations
of federal securities laws.

On January 9, 2018, the U.S. Food and Drug Administration ("FDA")
released its briefing document for the January 11, 2018 meeting of the
Antimicrobial Drugs Advisory Committee to discuss the New Drug
Application for Linhaliq™ for the proposed indication of treatment of
non-cystic fibrosis bronchiectasis ("NCFB"). The FDA stated that "there
were too many uncertainties with regard to duration of treatment,
frequency of administration and endpoints to allow for reliance on a
single Phase 3 trial" of the drug, and that the FDA recommended Aradigm
conduct "two independent trials" to provide evidence supporting the
drug's "overall demonstration of efficacy and safety."

On this news, shares of Aradigm fell significantly, thereby injuring

If you purchased Aradigm securities, have information, would like to
learn more about these claims, or have any questions concerning this
announcement or your rights or interests with respect to these matters,
please contact Howard G. Smith, Esquire, of Law Offices of Howard G.
Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by
telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to,
or visit our website at

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

View Comments and Join the Discussion!